Cargando…
Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
Women with polycystic ovary syndrome (PCOS) have an adverse metabolic profile with an increased risk of prediabetes and type 2 diabetes (T2DM); however, it is unclear if PCOS is associated with increased cardiovascular events in later years independent of the presence of T2DM. Many therapies have be...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378434/ https://www.ncbi.nlm.nih.gov/pubmed/30800265 http://dx.doi.org/10.1177/2042018818805674 |
_version_ | 1783395927817453568 |
---|---|
author | Alalami, Huda Sathyapalan, Thozhukat Atkin, Stephen L. |
author_facet | Alalami, Huda Sathyapalan, Thozhukat Atkin, Stephen L. |
author_sort | Alalami, Huda |
collection | PubMed |
description | Women with polycystic ovary syndrome (PCOS) have an adverse metabolic profile with an increased risk of prediabetes and type 2 diabetes (T2DM); however, it is unclear if PCOS is associated with increased cardiovascular events in later years independent of the presence of T2DM. Many therapies have been used to treat the differing facets of PCOS, including those for menstrual irregularity, hirsutism, acne and anovulatory infertility. The aim of this review was to evaluate the cardiovascular profiles associated with the medications used in the management of PCOS and evaluate whether they have cardiovascular benefit, detriment or are neutral. The medications reviewed include oral contraceptive pills, antiandrogens, clomiphene and drugs specifically used in diabetes therapy; metformin, glitazones, dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 receptor agonists. This review concludes that therapies that are used to treat these patients appear not to add to the cardiovascular risk and that there is no evidence that any interventional medical therapy may prevent the onset of diabetes in patients with PCOS, though in the case of metformin, this agent may be beneficial in preventing development of gestational diabetes. |
format | Online Article Text |
id | pubmed-6378434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-63784342019-02-22 Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome Alalami, Huda Sathyapalan, Thozhukat Atkin, Stephen L. Ther Adv Endocrinol Metab Review Women with polycystic ovary syndrome (PCOS) have an adverse metabolic profile with an increased risk of prediabetes and type 2 diabetes (T2DM); however, it is unclear if PCOS is associated with increased cardiovascular events in later years independent of the presence of T2DM. Many therapies have been used to treat the differing facets of PCOS, including those for menstrual irregularity, hirsutism, acne and anovulatory infertility. The aim of this review was to evaluate the cardiovascular profiles associated with the medications used in the management of PCOS and evaluate whether they have cardiovascular benefit, detriment or are neutral. The medications reviewed include oral contraceptive pills, antiandrogens, clomiphene and drugs specifically used in diabetes therapy; metformin, glitazones, dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 receptor agonists. This review concludes that therapies that are used to treat these patients appear not to add to the cardiovascular risk and that there is no evidence that any interventional medical therapy may prevent the onset of diabetes in patients with PCOS, though in the case of metformin, this agent may be beneficial in preventing development of gestational diabetes. SAGE Publications 2018-11-06 /pmc/articles/PMC6378434/ /pubmed/30800265 http://dx.doi.org/10.1177/2042018818805674 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Alalami, Huda Sathyapalan, Thozhukat Atkin, Stephen L. Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome |
title | Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome |
title_full | Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome |
title_fullStr | Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome |
title_full_unstemmed | Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome |
title_short | Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome |
title_sort | cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378434/ https://www.ncbi.nlm.nih.gov/pubmed/30800265 http://dx.doi.org/10.1177/2042018818805674 |
work_keys_str_mv | AT alalamihuda cardiovascularprofileofpharmacologicalagentsusedforthemanagementofpolycysticovarysyndrome AT sathyapalanthozhukat cardiovascularprofileofpharmacologicalagentsusedforthemanagementofpolycysticovarysyndrome AT atkinstephenl cardiovascularprofileofpharmacologicalagentsusedforthemanagementofpolycysticovarysyndrome |